Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population

Abilleira S., Bevan S. and Markus H. S. 2006 The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J. Med. Genet. 43, 897–901.PubMedCrossRefGoogle Scholar

Alpert J. S., Thygesen K., Antman E. and Bassand J. P. 2000 Myocardial infarction redefined — a consensus document of The Joint European society of cardiology/American college of cardiology committee for the redefinition of myocardial infarction. J. Am. Coll. Cardiol. 36, 959–969.PubMedCrossRefGoogle Scholar

Ciruzzi M., Schargrodsky H., Pramparo P., Rivas Estany E., Rodriguez Naude L., de la Noval Garcia R. et al. 2003 Attributable risks for acute myocardial infarction in four countries of Latin America. Medicina (Buenos Aires) 63, 697–703.Google Scholar

Gonzalez-Hernandez N. A., Millan-Guerrero R. O., Ceja-Espiritu G., Baltazar-Rodriguez L. M., Rodriguez-Salazar R., Olmedo-Buenrostro B. A. et al. 2008 A polymorphism in the matrix metalloproteinase-2 (MMP-2 — 1306T>C) gene promoter is associated with high risk of ischemic stroke in hypertensive patients. Genes Genom. 30, 533–540.Google Scholar

Hlatky M. A., Ashley E., Quertermous T., Boothroyd D. B., Ridker P., Southwick A. et al. 2007 Atherosclerotic disease, vascular function and genetic epidemiology (ADVANCE) study. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am. Heart J. 154, 1043–1051.PubMedCrossRefGoogle Scholar

Hojo Y., Ikeda U., Ueno S., Arakawa H. and Shimada K. 2001 Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn. Circ. J. 65, 71–75.PubMedCrossRefGoogle Scholar

Horne B. D., Camp N. J., Carlquist J. F., Muhlestein J. B., Kolek M. J., Nicholas Z. P. and Anderson J. L. 2007 Multiplepolymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am. Heart J. 154, 751–758.PubMedCrossRefGoogle Scholar

Hsieh K., Lalouschek W., Schillinger M., Endler G., Reisinger M., Janisiw M. et al. 2005 Impact of ENaC Polymorphisms on the risk of ischemic cerebrovascular events: a multicenter case-control study. Clin. Chem. 51, 952–956.PubMedCrossRefGoogle Scholar

Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F. et al. 1998 Peripheral blood levels of matrix metalloproteases-2 and −9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32, 368–372.PubMedCrossRefGoogle Scholar

Medina-Mora M. A., Peña-Corona M. P., Cravioto P., Villatoro J. and Kuri P. 2002 Del tabaco al uso de otras drogas: ?el uso temprano de tabaco aumenta la probabilidad de usar otras drogas? Salud Publica Mex. 44, S109–S115.PubMedGoogle Scholar

Newby A. C. 2005 Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev. 85, 1–31.PubMedCrossRefGoogle Scholar

Park H. Y., Kwon H. M., Lim H. J., Hong B. K., Lee J. Y., Park B. E. et al. 2001 Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp. Mol. Med. 33, 95–102.PubMedGoogle Scholar

Pasterkamp G., Schoneveld A. H., Hijnen D. J., de Kleijn D. P., Teepen H., van der Wal A. C. and Borst C. 2000 Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 150, 245–253.PubMedCrossRefGoogle Scholar

Peterson J. T. 2006 The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69, 677–687.PubMedCrossRefGoogle Scholar

Price S. J., Greaves D. R. and Watkins H. 2001 Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J. Biol. Chem. 276, 7549–7558.PubMedCrossRefGoogle Scholar

Suzuki H., Kusuyama T., Sato R., Yokota Y., Tsunoda F., Sato T. et al. 2008 Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of myocardial infarction. Eur. J. Clin. Invest. 38, 166–173.PubMedCrossRefGoogle Scholar

Tedgui A. and Mallat Z. 2006 Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86, 515–581.PubMedCrossRefGoogle Scholar

Vasku A., Goldbergová M., Izakovicová Holla L., Sisková L., Groch L., Beránek M. et al. 2004 A haplotype constituted of four MMP-2 promoter polymorphisms (− 1575G/A, −1306C/T, −790T/G and −735C/T) is associated with coronary triple-vessel disease. Matrix Biol. 22, 585–591.PubMedCrossRefGoogle Scholar

Yasmin, McEniery C. M., Wallace S., Dakham Z., Pulsalkar P., Maki-Petaja K. et al. 2005 Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 25, 372–378.PubMedCrossRefGoogle Scholar

Zhou H. Z., Ma X., Gray M. O., Zhu B. Q., Nguyen A. P., Baker A. J., Simonis U. et al. 2007 Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem. Biophys. Res. Commun. 358, 189–195.PubMedCrossRefGoogle Scholar